Mayo Clinic Study: GLP-1 Peptides Cut Diabetes Risk 31% vs Metformin
A Mayo Clinic review of 256,492 prediabetic adults links GLP-1 peptide drugs to 31% lower diabetes progression and 41% lower mortality than metformin, with caveats.
A Mayo Clinic review of 256,492 prediabetic adults links GLP-1 peptide drugs to 31% lower diabetes progression and 41% lower mortality than metformin, with caveats.